300601.SZ SHZ
Shenzhen Kangtai Biological Products Co., Ltd.
1W: +3.8%
1M: +7.0%
3M: +15.8%
YTD: -11.7%
1Y: -21.6%
3Y: -47.1%
5Y: -84.8%
¥13.58 ($2.02)
+0.79 (+6.18%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$603M
-41.6% ▼
5Y CAGR: +3.6%
Capital Expenditures
$472M
+34.3% ▲
5Y CAGR: +4.1%
Free Cash Flow
$131M
-58.3% ▼
5Y CAGR: +1.9%
Dividends Paid
$257M
-27.6% ▼
Buybacks
$0
+100.0% ▲
Net Change in Cash
-$754M
-528.0% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $679M | $1.3B | -$133M | $861M | $202M |
| Depreciation & Amort. | $93M | $405M | $201M | $201M | $317M |
| Stock-Based Comp. | $105M | $30M | $5M | $3M | $0 |
| Change in Working Capital | -$462M | -$276M | -$605M | -$412M | -$341M |
| Other Non-Cash Items | -$69M | $179M | $1.3B | $379M | $425M |
| Operating Cash Flow | $440M | $1.7B | $546M | $1.0B | $603M |
| — Investing Activities — | |||||
| Capital Expenditures | -$1.2B | -$2.5B | -$1.3B | -$718M | -$472M |
| Acquisitions (Net) | $1.2B | $186K | $80K | $0 | $0 |
| Investment Purchases | -$2.6B | -$1.1B | -$3.5B | -$820M | -$947M |
| Investment Sales | $14M | $2.2B | $2.2B | $1.0B | $847M |
| Other Investing | -$1.2B | $2M | -$2M | $62M | $16M |
| Investing Cash Flow | -$3.8B | -$1.4B | -$2.6B | -$439M | -$557M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$165M | $3.1B | -$541M | $80M | -$531M |
| Stock Repurchased | -$210K | $2M | -$21M | -$101M | $0 |
| Dividends Paid | -$70M | -$206M | -$595M | -$201M | -$257M |
| Other Financing | $4.2B | -$455M | $719M | -$196M | -$14M |
| Financing Cash Flow | $3.8B | $2.5B | -$465M | -$418M | -$801M |
| Net Change in Cash | $382M | $2.7B | -$2.5B | $176M | -$754M |
| Cash End of Period | $858M | $3.5B | $994M | $1.2B | $416M |
| Free Cash Flow | -$787M | -$888M | -$765M | $315M | $131M |